Valeant expects Mylan’s launch of generic herpes drug to hurt profit

(Reuters) – Valeant Pharmaceuticals International Inc, Canada’s biggest listed drugmaker, said it expects Mylan Inc’s launch of a generic version of Valeant’s genital herpes drug to reduce its cash earnings-per-share for the year by 30 to 40 cents. The company said it would launch its own generic of the ointment, Zovirax, on Thursday. Mylan, a generic drugmaker, said on Wednesday it received final approval for the first generic version of Zovirax from the U.S. Food and Drug Administration. …
Sexual Health News Headlines – Yahoo! News